Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q3 FY25 results · Oct–Dec 2024
Wockhardt reported revenue from operations of ₹721.00 crore (up 2.9% from Q3 FY24) and net profit of ₹20.00 crore for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 721.00 | 701.00 | +2.9% | 809.00 | −10.9% |
| Other income | 8.00 | 8.00 | +0.0% | 9.00 | −11.1% |
| Total income | 729.00 | 709.00 | +2.8% | 818.00 | −10.9% |
| Profit before tax | 21.00 | (87.00) | Turned profit | (9.00) | Turned profit |
| Net profit for the period | 20.00 | (86.00) | Turned profit | (16.00) | Turned profit |
| Attributable to shareholders of the company | 14.00 | (83.00) | Turned profit | (22.00) | Turned profit |
| EPS, basic (₹) | 0.91 | (5.75) | not comparable | (1.47) | Turned profit |
| Net margin (%) | 2.8 | -12.3 | -2.0 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 325.00 | 288.00 | +12.8% | 370.00 | −12.2% |
| Other income | 6.00 | 5.00 | +20.0% | 11.00 | −45.5% |
| Total income | 331.00 | 293.00 | +13.0% | 381.00 | −13.1% |
| Profit before tax | (22.00) | (74.00) | Loss narrowed | (36.00) | Loss narrowed |
| Net profit for the period | (22.00) | (74.00) | Loss narrowed | (36.00) | Loss narrowed |
| EPS, basic (₹) | (1.40) | (5.14) | not comparable | (2.34) | Loss narrowed |
| Net margin (%) | -6.8 | -25.7 | -9.7 |
Consolidated
- Filed with BSE
- 07 Feb 2025, 14:01 IST
- Board meeting
- 07 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2025, 14:01 IST
- Board meeting
- 07 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE